{"ATC Code":"G03BA03","Abbreviation":"","Aliases":["Testosteron","Homosterone","Testiculosterone","Androlin","Synandrol F","Testosteroid","Andronaq","Andrusol","Homosteron","Orquisteron"],"Biological Half-Life":"The half life of testosterone is highly variable, ranging from 10-100 minutes.","CAS":"58-22-0","ChEBI":"CHEBI:17347","ChEMBL":"CHEMBL386630","ChemicalClasses":["steroid"],"Chirality":"absolute","Color/Form":"White needles from dilute acetone","Decomposition":"When heated to decomposition it emits acrid smoke and irritating fumes.","Dosing Info":[],"Drug Classes":"Breast Feeding; Lactation; Milk, Human; Androgens; Hormones","Drug Indication":"Testosterone is indicated to treat primary hypogonadism and hypogonadotropic hypogonadism.","Drug Warnings":"/BOXED WARNING/ WARNING: SECONDARY EXPOSURE TO TESTOSTERONE. Virilization has been reported in children who were secondarily exposed to testosterone gel. Children should avoid contact with unwashed or unclothed application sites in men using testosterone gel. Healthcare providers should advise patients to strictly adhere to recommended instructions for use.","DrugClasses":["hormone"],"EINECS":"200-370-5","Esters":["acetate","benzoate","valerate","cypionate","enantate","undecylate","propionate","dipropionate","stearate","palmitate"],"European Community (EC) Number":"200-370-5","FDA Pharmacological Classification":"3XMK78S47O","HMDB ID":"HMDB0000234","HeavyAtomCount":21,"Human Drugs":"Breast Feeding; Lactation; Milk, Human; Androgens; Hormones","IUPACName":"(8R,9S,10R,13S,14S,17S)-17-hydroxy-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one","Impurities":["boldenone","epitestosterone","testosterone acetate","boldione","androstenedione","4-androstenediol","androstanolone","3-methoxyandrosta-3,5-dien-17-one","(17β)-17-hydroxyandrosta-4,6-dien-3-one","3-ethoxyandrosta-3,5-dien-17-one"],"InChI":"InChI=1S/C19H28O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h11,14-17,21H,3-10H2,1-2H3/t14-,15-,16-,17-,18-,19-/m0/s1","InChIKey":"MUMGGOZAMZWBJJ-DYKIIFRCSA-N","MeSH Pharmacological Classification":"Compounds that interact with ANDROGEN RECEPTORS in target tissues to bring about the effects similar to those of TESTOSTERONE. Depending on the target tissues, androgenic effects can be on SEX DIFFERENTIATION; male reproductive organs, SPERMATOGENESIS; secondary male SEX CHARACTERISTICS; LIBIDO; development of muscle mass, strength, and power. (See all compounds classified as Androgens.)","Melting Point":"151.0 °C","MolecularFormula":"C\u003csub\u003e19\u003c/sub\u003eH\u003csub\u003e28\u003c/sub\u003eO\u003csub\u003e2\u003c/sub\u003e","MolecularWeight":"288.4 g/mol","Odor":"Odorless","Opticalactivity":"UNSPECIFIED","Pharmacodynamics":"Testosterone antagonizes the androgen receptor to induce gene expression that causes the growth and development of masculine sex organs and secondary sexual characteristics. The duration of action of testosterone is variable from patient to patient with a half life of 10-100 minutes. The therapeutic index is wide considering the normal testosterone levels in an adult man range from 300-1000ng/dL. Counsel patients regarding the risk of secondary exposure of testosterone topical products to children.","Physical Description":"Solid","PrevSalts":[],"PubChemId":6013,"Record Description":["Testosterone is an androstanoid having 17beta-hydroxy and 3-oxo groups, together with unsaturation at C-4-C-5.. It has a role as an androgen, a human metabolite, a Daphnia magna metabolite and a mouse metabolite. It is a 17beta-hydroxy steroid, an androstanoid, a C19-steroid and a 3-oxo-Delta(4) steroid.","Testosterone is a steroid sex hormone indicated to treat primary hypogonadism and hypogonadotropic hypogonadism. Testosterone antagonizes the androgen receptor to induce gene expression that causes the growth and development of masculine sex organs and secondary sexual characteristics.  Testosterone was isolated from samples and also synthesized in 1935.","Testosterone is an Androgen. The mechanism of action of testosterone is as an Androgen Receptor Agonist.","Testosterone has been reported in Locusta migratoria, Botrytis cinerea, and other organisms with data available.","Therapeutic Testosterone is a synthetic form of the endogenous androgenic steroid testosterone. In vivo, testosterone is irreversibly converted to dihydrotestosterone (DHT) in target tissues by the enzyme 5-alpha reductase. Testosterone or DHT ligand-androgen receptor complexes act as transcription factor complexes, stimulating the expression of various responsive genes. DHT binds with higher affinity to androgen receptors than testosterone, activating gene expression more efficiently. In addition, testosterone is irreversibly converted to estradiol by the enzyme complex aromatase, particularly in the liver and adipose tissue. Testosterone and DHT promote the development and maintenance of male sex characteristics related to the internal and external genitalia, skeletal muscle, and hair follicles; estradiol promotes epiphyseal maturation and bone mineralization. Due to rapid metabolism by the liver, therapeutic testosterone is generally administered as an ester derivative.","TESTOSTERONE is a small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1972 and has 7 approved and 29 investigational indications. This drug has a black box warning from the FDA.","Testosterone is the most important androgen in potency and quantity•_Оa steroid sex hormone found in both men and women. Testosterone is synthesized and released by the Leydig cells that lie between the tubules and comprise less than 5% of the total testicular volume. testosterone diffuses into the seminiferous tubules where it is essential for maintaining spermatogenesis. Some binds to an androgen-binding protein (ABP) that is produced by the Sertoli cells and is homologous to the sex-hormone binding globulin that transports testosterone in the general circulation. The ABP carries testosterone in the testicular fluid where it maintains the activity of the accessory sex glands and may also help to retain testosterone within the tubule and bind excess free hormone. Some testosterone is converted to estradiol by Sertoli cell-derived aromatase enzyme. Leydig cell steroidogenesis is controlled primarily by luteinizing hormone with negative feedback of testosterone on the hypothalamic-pituitary axis. The requirement of spermatogenesis for high local concentrations of testosterone means that loss of androgen production is likely to be accompanied by loss of spermatogenesis. Indeed, if testicular androgen production is inhibited by the administration of exogenous androgens then spermatogenesis ceases. This is the basis of using exogenous testosterone as a male contraceptive. testosterone is converted to dihydrotestosterone by 5a-reductase type 2 (EC 1.3.1.22, SRD5A2), the androgen with the highest affinity for the androgen receptor. SRD5A2 deficiency illustrates the importance of dihydrotestosterone for external virilization, as individuals with this condition have normal male internal structures but their external genitalia are of female appearance. There is now clear evidence that the human fetal testis and also the fetal adrenal gland is capable of testosterone biosynthesis during the first trimester. Regardless of the source of androgen production, the target tissue responds by male sexual differentiation of the external genitalia by the end of the first trimester. It is clear that testicular damage may result in loss of testosterone production or the loss of spermatogenesis or both. Loss of androgen production results in hypogonadism, the symptoms of which reflect the functions of testosterone. Male hypogonadism is defined as failure of the testes to produce normal amounts of testosterone, combined with signs and symptoms of androgen deficiency. Systemic testosterone levels fall by about 1% each year in men. Therefore, with increasing longevity and the aging of the population, the number of older men with testosterone deficiency will increase substantially over the next several decades. Serum testosterone levels decrease progressively in aging men, but the rate and magnitude of decrease vary considerably. Approximately 1% of healthy young men have total serum testosterone levels below normal; in contrast, approximately 20% of healthy men over age 60 years have serum testosterone levels below normal.  (A3376, A3377). In men, testosterone is produced primarily by the Leydig (interstitial) cells of the testes when stimulated by luteinizing hormone (LH). It functions to stimulate spermatogenesis, promote physical and functional maturation of spermatozoa, maintain accessory organs of the male reproductive tract, support development of secondary sexual characteristics, stimulate growth and metabolism throughout the body and influence brain development by stimulating sexual behaviors and sexual drive. In women, testosterone is produced by the ovaries (25%), adrenals (25%) and via peripheral conversion from androstenedione (50%). Testerone in women functions to maintain libido and general wellbeing. Testosterone exerts a negative feedback mechanism on pituitary release of LH and follicle-stimulating hormone (FSH). Testosterone may be further converted to dihydrotestosterone or estradiol depending on the tissue","A potent androgenic steroid and major product secreted by the LEYDIG CELLS of the TESTIS. Its production is stimulated by LUTEINIZING HORMONE from the PITUITARY GLAND. In turn, testosterone exerts feedback control of the pituitary LH and FSH secretion. Depending on the tissues, testosterone can be further converted to DIHYDROTESTOSTERONE or ESTRADIOL.","See also: Testosterone Propionate (is active moiety of); Testosterone Enanthate (active moiety of); Testosterone Cypionate (active moiety of) ... View More ...","Testosterone is an androstanoid having 17beta-hydroxy and 3-oxo groups, together with unsaturation at C-4-C-5.. It has a role as an androgen, a human metabolite, a Daphnia magna metabolite and a mouse metabolite. It is a 17beta-hydroxy steroid, an androstanoid, a C19-steroid and a 3-oxo-Delta(4) steroid.","LiverTox|Endocrine|Hormone replacement|Androgen","Wikipedia|List of designer drugs|Androgens|Testosterone based"],"References":[{"Name":"Wikipedia","Urls":[{"Link":"https://en.wikipedia.org/wiki/Testosterone","Name":"Testosterone","Sub":false}]},{"Name":"Wikidata","Urls":[{"Link":"https://www.wikidata.org/wiki/Q1318776","Name":"Testosterone","Sub":false}]},{"Name":"DrugBank","Urls":[{"Link":"https://go.drugbank.com/drugs/DB00624","Name":"Testosterone","Sub":false}]},{"Name":"PubChem","Urls":[{"Link":"https://pubchem.ncbi.nlm.nih.gov/compound/6013","Name":"Testosterone","Sub":false}]},{"Name":"ChEMBL","Urls":[{"Link":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL386630","Name":"Testosterone","Sub":false}]},{"Name":"ChEBI","Urls":[{"Link":"https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:17347","Name":"Testosterone","Sub":false}]},{"Name":"Common Chemistry","Urls":[{"Link":"https://commonchemistry.cas.org/detail?cas_rn=58-22-0","Name":"Testosterone","Sub":false}]},{"Name":"HMDB","Urls":[{"Link":"https://hmdb.ca/metabolites/HMDB0000234","Name":"Testosterone","Sub":false}]},{"Name":"KEGG","Urls":[{"Link":"https://www.kegg.jp/entry/C00535","Name":"Testosterone","Sub":false}]},{"Name":"UNII","Urls":[{"Link":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/3XMK78S47O","Name":"Testosterone","Sub":false}]},{"Name":"EPA DSSTox","Urls":[{"Link":"https://comptox.epa.gov/dashboard/chemical/details/DTXSID8022371","Name":"Testosterone","Sub":false}]}],"SMILES":"C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CCC4=CC(=O)CC[C@]34C","Solubility":"In water, 23.4 mg/L at 25 °C","Stability/Shelf Life":"Stable under recommended storage conditions.","StoreUNII":["3XMK78S47O"],"StructureBase64":"<svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" height="64.739mm" version="1.2" viewBox="0 0 116.807 64.739" width="116.807mm">
      
    <desc>Generated by the Chemistry Development Kit (http://github.com/cdk)</desc>
      
    <g fill="#000000" stroke="#000000" stroke-linecap="round" stroke-linejoin="round" stroke-width=".7">
            
        <rect fill="#FFFFFF" height="65.0" stroke="none" width="117.0" x=".0" y=".0"/>
            
        <g class="mol" id="mol1">
                  
            <path class="bond" d="M81.708 15.9l.696 .073l3.338 -14.973l-2.089 -.22l-2.088 -.22z" id="mol1bnd1" stroke="none"/>
                  
            <line class="bond" id="mol1bnd2" x1="82.056" x2="68.848" y1="15.936" y2="8.316"/>
                  
            <line class="bond" id="mol1bnd3" x1="68.848" x2="55.64" y1="8.316" y2="15.936"/>
                  
            <line class="bond" id="mol1bnd4" x1="55.64" x2="55.64" y1="15.936" y2="31.176"/>
                  
            <line class="bond" id="mol1bnd5" x1="55.64" x2="68.848" y1="31.176" y2="38.796"/>
                  
            <line class="bond" id="mol1bnd6" x1="68.848" x2="82.056" y1="38.796" y2="31.176"/>
                  
            <line class="bond" id="mol1bnd7" x1="82.056" x2="82.056" y1="15.936" y2="31.176"/>
                  
            <line class="bond" id="mol1bnd8" x1="82.056" x2="96.483" y1="31.176" y2="35.85"/>
                  
            <line class="bond" id="mol1bnd9" x1="96.483" x2="105.424" y1="35.85" y2="23.556"/>
                  
            <line class="bond" id="mol1bnd10" x1="105.424" x2="96.483" y1="23.556" y2="11.263"/>
                  
            <line class="bond" id="mol1bnd11" x1="82.056" x2="96.483" y1="15.936" y2="11.263"/>
                  
            <path class="bond" d="M96.308 10.959l.35 .607l10.575 -4.587l-.832 -1.442l-.833 -1.442z" id="mol1bnd12" stroke="none"/>
                  
            <line class="bond" id="mol1bnd13" x1="68.848" x2="68.848" y1="38.796" y2="54.036"/>
                  
            <line class="bond" id="mol1bnd14" x1="68.848" x2="55.64" y1="54.036" y2="61.656"/>
                  
            <line class="bond" id="mol1bnd15" x1="55.64" x2="42.432" y1="61.656" y2="54.036"/>
                  
            <g class="bond" id="mol1bnd16">
                        
                <line x1="29.224" x2="42.432" y1="61.656" y2="54.036"/>
                        
                <line x1="29.224" x2="39.994" y1="58.841" y2="52.628"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd17" x1="29.224" x2="16.016" y1="61.656" y2="54.036"/>
                  
            <g class="bond" id="mol1bnd18">
                        
                <line x1="17.236" x2="6.707" y1="54.74" y2="60.821"/>
                        
                <line x1="16.016" x2="5.487" y1="52.628" y2="58.709"/>
                      
                <line class="hi" stroke="#FF0D0D" x1="6.707000000000001" x2="11.9715" y1="60.821" y2="57.7805"/>
                <line class="hi" stroke="#FF0D0D" x1="5.487" x2="10.7515" y1="58.709" y2="55.6685"/>
            </g>
                  
            <line class="bond" id="mol1bnd19" x1="16.016" x2="16.016" y1="54.036" y2="38.796"/>
                  
            <line class="bond" id="mol1bnd20" x1="16.016" x2="29.224" y1="38.796" y2="31.176"/>
                  
            <line class="bond" id="mol1bnd21" x1="29.224" x2="42.432" y1="31.176" y2="38.796"/>
                  
            <line class="bond" id="mol1bnd22" x1="55.64" x2="42.432" y1="31.176" y2="38.796"/>
                  
            <line class="bond" id="mol1bnd23" x1="42.432" x2="42.432" y1="54.036" y2="38.796"/>
                  
            <path class="bond" d="M42.103 38.676l.658 .24l6.857 -13.722l-1.973 -.719l-1.974 -.718z" id="mol1bnd24" stroke="none"/>
                  
            <g class="bond" id="mol1bnd25">
                        
                <line x1="55.99" x2="55.29" y1="31.176" y2="31.176"/>
                        
                <line x1="56.24" x2="55.04" y1="33.353" y2="33.353"/>
                        
                <line x1="56.49" x2="54.79" y1="35.53" y2="35.53"/>
                        
                <line x1="56.74" x2="54.54" y1="37.708" y2="37.708"/>
                        
                <line x1="56.99" x2="54.29" y1="39.885" y2="39.885"/>
                        
                <line x1="57.24" x2="54.04" y1="42.062" y2="42.062"/>
                      
            </g>
                  
            <path class="bond" d="M68.498 38.796h.7l1.308 -11.39h-1.658h-1.658z" id="mol1bnd26" stroke="none"/>
                  
            <g class="bond" id="mol1bnd27">
                        
                <line x1="82.406" x2="81.706" y1="31.176" y2="31.176"/>
                        
                <line x1="82.656" x2="81.456" y1="33.353" y2="33.353"/>
                        
                <line x1="82.906" x2="81.206" y1="35.53" y2="35.53"/>
                        
                <line x1="83.156" x2="80.956" y1="37.708" y2="37.708"/>
                        
                <line x1="83.406" x2="80.706" y1="39.885" y2="39.885"/>
                        
                <line x1="83.656" x2="80.456" y1="42.062" y2="42.062"/>
                      
            </g>
                  
            <g class="atom" id="mol1atm11">
                        
                <path d="M111.941 3.639q-.0 .756 -.256 1.328q-.256 .565 -.756 .881q-.5 .315 -1.245 .315q-.756 .0 -1.262 -.315q-.506 -.316 -.756 -.887q-.244 -.572 -.244 -1.334q.0 -.75 .244 -1.309q.25 -.566 .756 -.881q.506 -.316 1.274 -.316q.733 .0 1.233 .316q.5 .309 .756 .875q.256 .565 .256 1.327zM108.077 3.639q.0 .923 .387 1.459q.393 .53 1.22 .53q.84 -.0 1.221 -.53q.387 -.536 .387 -1.459q-.0 -.928 -.387 -1.452q-.381 -.524 -1.209 -.524q-.833 -.0 -1.226 .524q-.393 .524 -.393 1.452z" fill="#FF0D0D" stroke="none"/>
                        
                <path d="M116.247 6.092h-.619v-2.286h-2.512v2.286h-.614v-4.899h.614v2.071h2.512v-2.071h.619v4.899z" fill="#FF0D0D" stroke="none"/>
                      
            </g>
                  
            <path class="atom" d="M5.078 61.655q.0 .756 -.256 1.328q-.256 .565 -.756 .881q-.5 .315 -1.244 .315q-.756 .0 -1.262 -.315q-.506 -.316 -.756 -.887q-.244 -.572 -.244 -1.334q.0 -.75 .244 -1.309q.25 -.566 .756 -.881q.506 -.316 1.274 -.316q.732 .0 1.232 .316q.5 .309 .756 .875q.256 .565 .256 1.327zM1.215 61.655q-.0 .923 .387 1.459q.393 .53 1.22 .53q.84 -.0 1.221 -.53q.387 -.536 .387 -1.459q-.0 -.928 -.387 -1.452q-.381 -.524 -1.209 -.524q-.833 -.0 -1.226 .524q-.393 .524 -.393 1.452z" fill="#FF0D0D" id="mol1atm17" stroke="none"/>
                  
            <path class="atom" d="M57.512 48.866h-.619v-2.286h-2.512v2.286h-.613v-4.9h.613v2.072h2.512v-2.072h.619v4.9z" id="mol1atm22" stroke="none"/>
                  
            <path class="atom" d="M70.72 26.006h-.619v-2.286h-2.512v2.286h-.613v-4.9h.613v2.072h2.512v-2.072h.619v4.9z" id="mol1atm23" stroke="none"/>
                  
            <path class="atom" d="M83.928 48.866h-.619v-2.286h-2.512v2.286h-.613v-4.9h.613v2.072h2.512v-2.072h.619v4.9z" id="mol1atm24" stroke="none"/>
                
        </g>
          
    </g>
    
</svg>
","Therapeutic Uses":"Androgens","Title":"Testosterone","UNII":"3XMK78S47O","Wikidata":"Q1318776","Wikipedia":"Testosterone","XLogP":3.3}